perillyl alcohol has been researched along with Prostatic Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gauthier, D; Hentosh, P; Peffley, DM; Sundin, T | 1 |
| Howard, SP; Rajesh, D | 1 |
| Alberti, D; Arzoomanian, R; Bailey, H; DeMets, D; Horvath, D; Liu, G; McGovern, J; Oettel, K; Rezazadeh, H; Robinson, E; Staab, MJ; Tutsch, K; Ummersen, LV; Wilding, G | 1 |
| Chung, BH; Lee, HY; Lee, JS; Young, CY | 1 |
| Cheson, BD; Ho, P; Nelson, A; Saunders, J; Sepelak, SB; Zweibel, J | 1 |
| Ripple, GH; Wilding, G | 1 |
1 review(s) available for perillyl alcohol and Prostatic Neoplasms
| Article | Year |
|---|---|
Drug development in prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Cell Cycle; Cell Differentiation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Flavonoids; Humans; Male; Monoterpenes; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Prostatic Neoplasms; Signal Transduction; Survival Rate; Terpenes; Vitamin D | 1999 |
1 trial(s) available for perillyl alcohol and Prostatic Neoplasms
| Article | Year |
|---|---|
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Monoterpenes; Prostatic Neoplasms; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2003 |
5 other study(ies) available for perillyl alcohol and Prostatic Neoplasms
| Article | Year |
|---|---|
The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells.
Topics: Blotting, Western; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Male; Monoterpenes; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Telomerase; TOR Serine-Threonine Kinases | 2012 |
Perillyl alcohol mediated radiosensitization via augmentation of the Fas pathway in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cyclin B; Cyclin D; Cyclins; fas Receptor; G2 Phase; Humans; Male; Membrane Proteins; Mitosis; Monoterpenes; Prostatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2003 |
Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Genes, Reporter; Humans; Luciferases; Male; Monoterpenes; Nandrolone; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-jun; Receptors, Androgen; Tissue Kallikreins; Transcriptional Activation; Transfection | 2006 |
Clinical development plan: l-perillyl alcohol.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cricetinae; Drug Approval; Female; Humans; Male; Mice; Monoterpenes; Neoplasms, Experimental; Prostatic Neoplasms; Rats; Research Design; Terpenes; Toxicity Tests | 1996 |
Clinical trials referral resource. Clinical trials with perillyl alcohol.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Monoterpenes; Ovarian Neoplasms; Prostatic Neoplasms; Terpenes | 1997 |